Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Fallopian Tube Neoplasms 1Carcinoma 1

Interventions

Carboplatin 18Paclitaxel 17Bevacizumab 17olaparib 8Specimen Handling 7liposomal doxorubicin 6pembrolizumab 5Taxes 5Biopsy 5cemiplimab 4Magnetic Resonance Spectroscopy 4sarilumab 3niraparib 3mirvetuximab soravtansine 3Topotecan 3Standard of Care 3Letrozole 3Gemcitabine 3Cisplatin 3130-nm albumin-bound paclitaxel 3taxane 2talazoparib 2palbociclib 2abemaciclib 2Temozolomide 2Surgical Procedures, Operative 2Practice Guidelines as Topic 2Poly(ADP-ribose) Polymerase Inhibitors 2Palliative Care 2Immunoglobulin G 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Fallopian Tube Neoplasms × Maintenance × Clear all
NCT03983226 2022-03-18

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Shanghai Gynecologic Oncology Group

Phase 2 Recruiting
167 enrolled
Gynecologic

Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡